Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Galmed Pharmaceutica (GLMD)

Galmed Pharmaceutica (GLMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 102,398
  • Shares Outstanding, K 21,113
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,460 K
  • 60-Month Beta 2.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.31
  • Number of Estimates 3
  • High Estimate -0.30
  • Low Estimate -0.33
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -55.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.36 +11.24%
on 07/14/20
6.29 -22.89%
on 07/15/20
+0.07 (+1.46%)
since 06/30/20
3-Month
3.93 +23.41%
on 05/01/20
6.29 -22.89%
on 07/15/20
+0.49 (+11.24%)
since 04/30/20
52-Week
3.02 +60.60%
on 03/19/20
7.38 -34.28%
on 12/04/19
-1.29 (-21.01%)
since 07/30/19

Most Recent Stories

More News
Galmed Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on Thursday August 6

, /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1...

GLMD : 4.85 (-0.41%)
Intercept Slumps as the FDA Issues CRL to NASH Candidate

Intercept (ICPT) down on receipt of CRL for its NDA seeking approval of OCA for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).

VKTX : 7.02 (-6.90%)
GLMD : 4.85 (-0.41%)
ICPT : 45.64 (-2.27%)
GNFT : 4.91 (+2.51%)
How Galmed (GLMD) Stock Stands Out in a Strong Industry

Galmed (GLMD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GLMD : 4.85 (-0.41%)
Galmed Pharmaceuticals: 1Q Earnings Snapshot

TEL AVIV, Israel (AP) _ Galmed Pharmaceuticals Ltd. (GLMD) on Thursday reported a loss of $6.1 million in its first quarter.

GLMD : 4.85 (-0.41%)
Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results

, /PRNewswire/ --Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™,...

GLMD : 4.85 (-0.41%)
Galmed Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Business Update on Thursday May 14

, /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1...

GLMD : 4.85 (-0.41%)
Galmed Pharmaceuticals: 4Q Earnings Snapshot

TEL AVIV, Israel (AP) _ Galmed Pharmaceuticals Ltd. (GLMD) on Thursday reported a loss of $8.3 million in its fourth quarter.

GLMD : 4.85 (-0.41%)
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2019 Financial Results

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently...

GLMD : 4.85 (-0.41%)
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently...

GLMD : 4.85 (-0.41%)
BioCryst Pharmaceuticals (BCRX) in Focus: Stock Moves 8.5% Higher

BioCryst Pharmaceuticals (BCRX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

BCRX : 4.07 (-3.55%)
GLMD : 4.85 (-0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade GLMD with:

Business Summary

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel.

See More

Key Turning Points

2nd Resistance Point 4.98
1st Resistance Point 4.92
Last Price 4.85
1st Support Level 4.75
2nd Support Level 4.64

See More

52-Week High 7.38
Fibonacci 61.8% 5.71
Fibonacci 50% 5.20
Last Price 4.85
Fibonacci 38.2% 4.69
52-Week Low 3.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar